BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)

[GlobeNewswire] – Potential to Add Fourth MPS Treatment to BioMarin Franchise more

View todays social media effects on BMRN

View the latest stocks trending across Twitter. Click to view dashboard

See who BioMarin is hiring next, click here to view